Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Nephrology (Carlton, Vic.)|July 25, 2015
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) studyAndrea K Viecelli, Elaine M Pascoe, Kevan R Polkinghorne, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|July 31, 2015
The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot TrialLei Zhang, Sunil V Badve, Elaine M Pascoe, et al.
Diabetes, Obesity & Metabolism|May 19, 2022
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysisChao Li, Jie Yu, Carinna Hockham, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2016
The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysisSunil V Badve, Suetonia C Palmer, Giovanni F M Strippoli, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|December 10, 2016
Representativeness of Honeypot Trial Participants to Australasian PD Patients, Lei Zhang, Sunil V Badve, et al.
Canadian Journal of Kidney Health and Disease|August 19, 2015
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialSunil V Badve, Lei Zhang, Jeff S Coombes, et al.
Diabetes Care|March 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized TrialsMatthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Kidney International Reports|February 22, 2021
Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPSSimon J Davies, Junhui Zhao, Hal Morgenstern, et al.
Nephrology (Carlton, Vic.)|May 13, 2016
Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialJoel Gummer, Robert Trengove, Elaine M Pascoe, et al.
Pageof 15